- 1 Changes in lung function and dyspnea perception in Colombian Covid-19 patients after a 12-
- 2 week pulmonary rehabilitation program.
- 3 12-week rehabilitation program in Covid-19
- 4 Carlos D Páez-Mora 1, Carolina Zona-Rubio1*, Teddy Angarita-Sierra 2, Matilde E Rojas-Paredes
- 5 1, Daniela Cano-Trejos 1.
- 6 1 cuidado Cardiorrespiratorio Research Group, Universidad Manuela Beltrán, Bogotá, Colombia.; 2
- 7 Biodiversity for Society research group, Universidad Nacional de Colombia, La Paz headquarters,
- 8 La Paz, Cesar, Colombia.
- 9 *Corresponding author: Carolina Zona-Rubio, Research, Respiratory Therapy, Universidad
- 10 Manuela Beltrán, Avenida circunvalar #60-00, 110231, Bogotá, Colombia. E-mail:
- 11 <u>dczonar@unal.edu.co</u>
- 12 BACKGROUND: Although moderate and severe COVID-19 patients have shown obstructive and
- 13 restrictive disorders in pulmonary function after recovery from the disease, studies evaluating the
- 14 effectiveness of rehabilitation programs that seek to improve lung function are scarce.
- 15 AIM: Herein, we evaluate changes in lung function and perceived dyspnea in Covid-19 patients after
- 16 undergoing 12 weeks of a PR program.
- 17 DESIGN: Retrospective observational study
- 18 SETTING: Cesar, Colombia Neumocesar Pneumological Center.
- 19 POPULATION: 100 outpatients with a history of Covid-19
- 20 METHODS: We evaluated respiratory function using spirometry parameters, as well as the mMRC
- 21 dyspnea scale for perceived dyspnea in 100 patients with a history of Covid-19. We used univariate
- 22 and multivariate statistical approaches to assess changes in lung function and perceived dyspnea

before and after a PR program to determine whether gender, age, height, weight, comorbidities, and
oxygen delivery system affect the recovery of lung function and perceived dyspnea.

RESULTS: We found that PR treatment has positive effects on respiratory pathologies caused by SARS-CoV-2 infection regardless of patient gender, indicating that rehabilitation provided benefits regardless of the physical characteristics of the patients. Both univariate and multivariate statistical analyses indicated that FVC, FEV1, FEF 25-75, and mMRC are robust diagnostic indicators of lung function recovery and perceived dyspnea. Both invasive and non-invasive positive pressure ventilatory support had deleterious effects on lung function prolongating patient recovery.

31 CONCLUSIONS: Rehabilitation programs can benefit patients facing respiratory pathologies caused

32 by SARS-CoV-2 infection. Additional research on the long-term effects of the sequelae of Covid-19

33 is needed. A large sample of patients is needed to clarify the effects of therapy on respiratory function.

CLINICAL REHABILITATION IMPACT: PR programs have positive effects on patients facing
 respiratory pathologies caused by SARS-CoV-2 infection.

36 Key words: pulmonary rehabilitation, SARS-CoV-2 infection, rehabilitation program.

37 Introduction

38 Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. Many 39 infected people develop mild to moderate respiratory illness and recover without requiring special 40 treatment. However, approximately 20% of Covid-19 patients require medical attention (1). Peramo 41 et al. (2) demonstrated that the persistence of some symptoms after recovery from the disease are 42 sequelae associated with the infection. The destruction of the alveolar epithelium, lung consolidation, 43 and extensive injury to alveolar epithelial cells are some of the pathophysiological manifestations 44 observed (2). The deterioration of lung function has been observed after hospitalization due to the 45 evolution of lung injury (3).

Disease progression leads to lung tissue damage, which stems from extensive injury to alveolar epithelial cells following infection. These alterations are more frequent in patients under mechanical ventilation. However, the presence of pulmonary alterations has been documented in pulmonary function tests of apparently healthy patients diagnosed with Covid-19 (2,4).

50 Spirometry is the best-known and low-cost respiratory function test, which involves evaluating the 51 mechanical properties of the respiratory system through volumes and capacities; it provides relevant 52 information for the classification of both obstructive and restrictive disorders (5). The most 53 commonly used parameters in this test are forced vital capacity (FVC), forced expiratory volume in 54 the first second (FEV1), and the FEV1/FVC ratio (6).

55 Studies evaluating the lung function of patients after Covid-19 infection are scarce. However, Torres 56 Castro et al. (3) reported obstructive and restrictive disorders of the lung in both moderate and severe 57 COVID-19 patients using spirometry. These authors also evaluated diffusion disorders using the 58 diffusing capacity for carbon monoxide test (DLCO) and found that these were the most frequent 59 alterations observed, even in patients with mild cases and patients without symptoms (7). Approximately 40% of hospitalized Covid-19 patients have impaired lung function (8). This lesion has even been observed in patients with mild disease, which has motivated evaluations of lung function to characterize changes in the lung parenchyma and assess the need for treatment. Restrictive patterns are frequently observed between weeks 6 and 8 after discharge according to pulmonary function tests (9,10).

Pulmonary rehabilitation (PR) is a personalized multidisciplinary treatment that seeks to improve the physical and psychological conditions of patients with respiratory diseases. It has been used worldwide in patients with lung diseases such as chronic obstructive pulmonary disease (COPD) and can significantly improve lung function and quality of life. (10,11). It has also been used on patients in the recovery phase of Covid-19 (8-10).

Evaluations of lung function and dyspnea perception in patients undergoing rehabilitation programs are needed to improve our understanding of the sequelae of Covid-19 (12). Due to the scarcity of evidence-based guidelines regarding rehabilitation after COVID-19, there is an urgent need for studies to evaluate the lung function and dyspnea perception before and after PR programs (10,13,14). The Stanford Hall consensus for post-Covid-19 rehabilitation highlighted the need for more research on the sequelae of the disease and its long-term impact (10).

The aim of this study was to assess changes in lung function and perceived dyspnea in a group of patients diagnosed with Covid-19 after undergoing a 12-week PR program in a clinic in Colombia. The Ethical Guidelines for Human Research from the Declaration of Helsinki were followed, and ethics committee approval was obtained.

81 Materials and methods

82 Study design

Retrospective observational study was carried out and pre- and post-intervention lung function was
evaluated. The data were accessed for research purposes on August 22, 2022, and a confidentiality
agreement was signed with the institution to maintain the anonymity of the participants.

86 *Setting and Patients*

87 This study was conducted at NeumoCesar Pulmonary Center, Valledupar, Colombia. Approval was
88 obtained from the ethics committee of Manuela Beltrán University in Bogotá, Colombia (TRCC-CE-

89 I-2210009). The sample size was estimated using Slovin's formula as follows:

90
$$n = \frac{N}{1 + Ne^2}$$

91 where n is the sample size, *N* is the total number of COVID-19 patients attended at NeumoCesar who 92 received therapy (231 patients in this case), *e* is the maximum variability or margin of error (5% or 93 0.05), and 1 is the probability of an event occurring. Resolving Slovin's formula, the sample size 94 obtained was 100. Therefore, 100 patients diagnosed with COVID-19, who completed the PR 95 program in 2022 and met the following inclusion and exclusion criteria, were included:

96 Inclusion criteria:

97 • Post-covid-19 patients

- Patients had been discharged from the hospital
- Patients with 100% compliance with the PR program at the NeumoCesar institution.

100 Exclusion criteria:

Serious arrhythmias, syncope induced by exercise or decompensated metabolic disorders without
 adequate management

• Coexistence of musculoskeletal or neurological problems that reduce mobility

• History of severe psychiatric disorder, cognitive disorders, or organic mental syndrome that prevents interaction or understanding instructions.

106 Intervention

107 Pre

Spirometry was performed, sociodemographic data were recorded, and FVC, FEV1, FEV1/FVC, FEF
25–75, and PEF were evaluated; dyspnea was evaluated using the Modified Medical Research
Council (mMRC) scale.

111 The PR program followed the recommendations of a previous publication of the Colombian Ministry 112 of Health and Social Protection entitled "Interventions for a Pulmonary Rehabilitation Program" (16). 113 This is a conventional rehabilitation program, however, was tailored to each patient's individual needs 114 and tolerance. During the sessions the modified BORG scale was used to assess the patient's effort. 115 Intensity was gradually adjusted by a therapist over the course of the rehabilitation in each session. 116 Intensity was defined according to hypoxemia, severity of the disease, age, among other variables. 117 Patients performed cardiorespiratory endurance training, accomplishing high-intensity intervals of 2 118 to 3 minutes with 60 to 80% of the maximum cardiac capacity. We monitored the oxygen saturation 119 of the patients with a pulse oximeter ensuring that the saturation range was always above 90%.

120 The rehabilitation program included different components such as pharmacological management, 121 patient and family education, nutritional follow-up, psychosocial support, daily living aid training, 122 vocational counseling, sexuality, and energy conservation techniques. These components were led by

a multidisciplinary team that included a Doctor, Respiratory Therapist, Physiotherapist, Nurse,
Nutritionist, Occupational Therapist, among others at NeumoCesar institution.

The PR program at the Pneumological Center comprised three sessions a week for 3 months. Vital signs were monitored and recorded before, during, and after each session. The sessions were 45 min and included (1) 20 min of aerobic exercise on a recumbent bike along with a respiratory stimulator comprising 3 balloons, 1200 ml. The respiratory stimulator was used for 4 series of 5 repetitions and adjusted to accommodate the tolerance of each patient; (2) 20 minutes of varied physical exercise including resistance, flexibility, and strength; (3) and 5 minutes of cool down.

131 Post

Spirometry was performed after completing the rehabilitation program. The mMRC dyspneaquestionnaire was also assessed.

134 Respiratory function and dyspnea assessments

Respiratory function was assessed through spirometry tests performed using the MiniBox SN 2021102368-PulmOne system with easy one connects; Minibox version: 3.1.1.19 software was used to record patient data such as age, gender, height, and weight at the beginning and end of the rehabilitation program. Dyspnea was assessed with the mMRC scale (Modified Medical Research Council) defined by the Medical Research Council (15), which was used as a self-assessment tool to measure the degree of disability of the patient due to dyspnea in daily activities on a scale from 0 to 4 (Table 1).

142 Tables

143 Table 1. Parameters and criteria employed to evaluate respiratory function and dyspnea.

Respiratory function

Forced vital capacity (FVC), expressed in liters, its normal values were $\geq 80\%$ of the predicted value.

Forced expiratory volume in one second (FEV1), expressed in liters, and its normal value was $\geq 80\%$ of the predicted value.

Ratio between forced expiratory volume in one second and forced vital capacity (FEV1/FVC) normal value > 70% of the predicted value.

Forced expiratory flow 25 - 75 (FEF25-75%), measured in liters, and its normal value >

65% of the predicted value (5).

Peak expiratory flow (PEF), the maximal flow that can be exhaled, measured in liters.

mMRC dyspnea scale

0 no dyspnea except during strenuous exercise

1 shortness of breath when running on a level surface or up a slight incline

2 walks slower than people of the same age on a level surface due to shortness of breath

or has to stop to catch breath when walking at a normal pace on a level surface.

3 stops to catch breath after walking ~100 m or after a few minutes on a level surface

4 too out of breath to leave the house, or out of breath while dressing or undressing

144

145 Statistical analysis

146 We evaluated differences in respiratory function by gender before and after therapy using a univariate 147 approach. We compared the age ranges by gender of the patients who completed the PR program 148 using a Welch's t-test (t). We compared the variability in forced volume capacity (FVC), forced 149 expiratory volume (FEV 1), peak expiratory flow (PEF), forced expiratory flow from 25 to 75% (FEF 150 25-75), and FEV1/FVC ratio using ANOVA (F= Fisher's F test; df= degrees of freedom; p =151 probability of significance). We analyzed the variability in mMRC using a non-parametric ANOVA, 152 and a Kruskal-Wallis test (H) was used to measure the central tendency of the samples (17). We 153 explored whether the age, height, or weight of the patients affected the variability observed in the 154 respiratory function through ANCOVA. We also assessed whether comorbidities by gender and the 155 oxygen delivery system used affect the FVC variability observed before and after therapy using nested 156 ANOVA. For all univariate analyses, we evaluated assumptions of normality and homogeneity of 157 variances using a Shapiro-Wilk test and Levene test, respectively.

158 We used a multivariable approach to assess the correlation and discrimination capacity of the 159 respiratory responses before and after therapy. We conducted a multidimensional scaling test (MDS) 160 to determine which of the respiratory responses showed greater variability; the respiratory response 161 that explains the differences observed indicates the success/failure of the intervention. MDS allows 162 similarities (or distances) in respiratory function to be represented as points in a high dimensional 163 space, which are reduced into a lower dimensional space, thereby providing a visual indication of the 164 similarity (or dissimilarity) (18,19). It also permits the identification of whether one cluster of patients 165 is dimensionally distinct from another via the identification of the respiratory function with the 166 highest variability and discrimination degree without linearity assumptions or a priori clustering (20). The goodness of fit between the fitted and observed distances was measured using "Kruskal's stress" 167 168 (S) (20,21), which is the average of the deviations between the end and the initial spatial distances 169 normalized to take values between 0 and 1. Values near 1 indicate the worst fit, and values near 0 170 indicate the best fit. However, values between 0.025 and 0.05 are considered good values, < 0.025

171	are excellent, and values equal to 0 are perfect (19). A linear discriminant analysis was conducted to
172	identify respiratory responses with the greatest discrimination capacity between pre- and post-therapy
173	performance.

174 All statistical analyses were performed using the software Rwizard 4.3 (19) and the following R

175 packages: car (21), hier.part (22), lawstat (23) nortest (24), overlap (25), stat (26), and usdm (27).

176 Data availability

- The data associated with the paper are not publicly available; however, they are available from thecorresponding author on reasonable request.
- 179

180 Ethical considerations

Before being included in the study, patients who met the inclusion criteria had to give their written consent to participate in the study. Written informed consent was obtained from adult participants $(\geq 18 \text{ years})$. The risks and benefits associated with participation in the study were clearly explained to each patient. The study was conducted in accordance with the Declaration of Helsinki ethical guidelines for research in humans. Likewise, approval was obtained from the ethics committee of Manuela Beltrán University (TRCC-CE-I-2210009).

187 **Results**

A total of 100 adult patients were included in the study (Men =42; women = 58; ratio = 1:1.4). The age range was broad for both genders, and no significant difference in the age range was observed between them (t = 0.058, df = 80.36, P = 0.95; Table 2). Respiratory function differed greatly before and after therapy; however, differences in pre- and post-therapy performance were low within each gender (Table 2). Men and women exhibited significant differences in FVC (F= 19.47, df= 3, P <0.0001), FEV1 (F= 22.49, df= 3, P=<0.0001), and mMRC (H = 99.022, df = 3, P < 0.0001) before and after therapy (Fig. 1). However, no differences were observed in PEF and FEF 25-75%, as well
as in the FEV1/FVC ratio (Fig. 2). ANCOVA showed that age, height, or weight was not correlated
with FVC, FEV1, or MRC (Table 3), indicating that these variables had no effect on the significant
differences observed before and after therapy.

198 Nested ANOVA indicated that the absence or presence of comorbidities in men and women

showing significant differences in FVC was associated with the oxygen delivery system that had been used to treat SARS-CoV-2 infection (F= 22.49, df= 3, P=<0.0001); the VMN and VMNI systems were correlated with FVC values under 70%, and the low-flow system and non-oxygen delivery were correlated with FVC values over 70%. However, comorbidities

203 did not affect differences observed between men and women in FVC and FEV1.

204 MDS revealed significant dissimilarities (S = 0.029) in the respiratory function of patients before and 205 after therapy (Figure 3A), indicating that therapy had positive effects on the respiratory pathologies 206 caused by SARS-CoV-2 infection. In addition, the MDS suggested that FEF 25-75% and mMRC are 207 robust diagnostic indicators of the patient recovery process because these respiratory function 208 variables were the most variable and had the highest discrimination degree. The linear discriminant 209 analysis confirmed that the therapy had positive effects on patients recovering from respiratory 210 pathologies caused by SARS-CoV-2 infection, as indicated by the pronounced differences observed 211 before and after therapy for each gender (Figure 3B-D). The first canonical axis explained 91.3% of 212 the variance and was correlated with differences in FVC and FEV1; the second canonical axis 213 explained 7.76% of the variance and was correlated with differences in MRC and FEF 25-75 (Figure 214 3C). The linear discriminant analysis also yielded the same diagnostic indicators for the patient 215 recovery process as were identified in the ANOVA and MDS. However, the cross-validation 216 percentage was moderate (55.5%), indicating that large patient sampling is required for the 217 discrimination function to achieve a higher classification accuracy of the respiratory function before 218 and after therapy.

Patients 'trait	Women (N = 42)	Men (N = 58)
Body measurements		
Height (m)	1.44–1.76 (X=1.61)	1.52–1.90 (X=1.73)
Weight (kg)	48–110 (X=74)	42–128 (X=80)
Age	22-86 (X=53.6)	19–81 (X=52.8)
Oxygen delivery system		
Invasive ventilation (IV)	6	10
Non-invasive ventilation (NIV)	17	28
Low flow	9	8
None	10	12
Comorbidities		
Asthma	6	3
COPD	5	2
Diabetes	1	2
High blood pressure	4	5
Hypothyroidism	2	0
Obesity	2	1
OSA	0	1
Non-comorbidities	22	45
Marital status		
None	26	40
Partner	16	19
Health insurance		
Contributory	38	51
Contributory + Prepaid insurance	1	2


219 Table 2. Descriptive data of the patients who completed the PR program and variables assessed.

Subsidized	3	6

Table 3. ANCOVA for assessing the effects of age, height, and weight of the patients on

respiratory function variables that showed significant differences before and after therapy.

Respiratory output	Age	Height	Weight
FVC	F= 0.77, P= 0.37	F= 0.95, P= 032	F=0.035, P= 0.85
FEV1	F= 0.007, P= 0.98	F= 0.27, P= 0.60	F= 0.031, P= 0.86



225

Figure 1. Differences by gender in the respiratory function before and after therapy using a univariate approach. (A-D) ANOVA for assessing respiratory responses before and after therapy. FVC=forced volume capacity; FEV 1=forced expiratory volume; PEF= peak expiratory flow; FEF 25-75= forced expiratory flow in 25 to 75% and FEV1/FVC1 ratio.



235 Figure 2




Figure 2. Differences by gender in peak expiratory flow function and dyspnea perception
before and after therapy. (A) ANOVA for assessing the response of peak expiratory flow
(PEF). (B) Non-parametric ANOVA using a Kruskal-Wallis test for assessing the perception
of dyspnea. mMRC = Medical Research Council Dyspnea Scale.






Figure 3. (A) Multidimensional scaling test (MDS) assessing the respiratory function of patients before and after therapy. The goodness of fit is indicated by the "Kruskal's stress (S)." Values near 1 indicate the worst fit, and values near 0 indicate the best fit. Values between 0.025 and 0.05 are considered good values, values < 0.025 are excellent, and values equal to 0 are perfect. (B-D) Linear discriminant analysis assessing the respiratory responses of patients before and after therapy. (B) Biplot depicting the observed variability in

- 250 respiratory function of patients before and after therapy. (C) Canonical scores and structure
- 251 of the linear discriminant analysis. (D) The length of the vector denotes the discrimination
- 252 capacity of each respiratory function.

255 **Discussion**

The results of this study provide evidence that PR program has positive effects on both men and women patients recovering from respiratory pathologies caused by SARS-CoV-2 infection. Significant differences in lung function parameters such as FVC, FEV1, and mMRC were observed before and after therapy. Age, height, nor weight was correlated with significant differences in FVC, FEV1, and mMRC, indicating that the therapy provided benefits to all patients regardless of their physical characteristics.

262 FEV1 can be used to evaluate the degree of airway obstruction when used in conjunction with 263 FEV1/FVC, which confirms the presence of obstruction. No significant differences were observed in 264 FEV1/FVC before and after therapy, which confirms the presence of a restrictive pulmonary pattern 265 and the absence of an obstructive pulmonary pattern, and changes in FEV1 before and after therapy 266 were significant. Restrictive patterns are characteristic of pulmonary disorders that result in damage 267 to the lung epithelium (16). The significant change in FVC reflects an improvement in pulmonary 268 function following therapy, and this change was associated with the restrictive pattern caused by 269 SARS-CoV-2 infection.

mMRC measures the perception of dyspnea, and it significantly improved after the therapy. This probably stemmed from the strengthening of the respiratory muscles. Rehabilitation also improves lung volume, oxygenation, and thus the perception of dyspnea. Resistance training during the early phases of rehabilitation likely improved the mechanical efficiency of the lungs; the observed improvement in lung function variables was similar to changes observed in patients undergoing rehabilitation programs following a diagnosis of COPD (28).

276 Our results are consistent with previous studies showing significant improvements in FVC, FEV1,

and mMRC in Covid-19 patients after PR (29–32). Our findings are also consistent with the results

of Liu et al. (12). In this study, a randomized controlled trial was conducted with 72 participants in

Huanggang, China, and changes in lung function were evaluated. Significant differences in some of the variables measured in our study, such as FVC, FEV1, and FEV1/FVC, before and after rehabilitation were detected. They also detected significant changes in DLCO and the 6-minute walk test before and after rehabilitation; however, these variables were not measured in our study.

283 The use of both invasive and non-invasive positive pressure ventilatory support during hospitalization 284 was significantly associated with FVC lower than 70% compared with the group that did not use this 285 support, which had FVC values higher than 70%. This might stem from the severity of Covid-19, 286 which is directly related to the need to use this type of support (33). These results indicate that positive 287 pressure ventilatory support might be associated with the deleterious effects on lung tissue. These are 288 secondary to the difficulty of titrating the ventilatory parameters due to the pulmonary heterogeneity 289 caused by the disease (34). In both cases, the lung tissue damage might be related to self-induced lung 290 injury (P-SILI) or ventilator-induced lung injury (VILI) (34). Thus, both invasive and non-invasive 291 positive pressure ventilatory support had deleterious effects on lung function, which prolonged patient 292 recovery. Therefore, the damage caused by the ventilation systems, as well as the severe Covid-19 293 symptoms that led to their use, explains why patients who required this type of support improved less than patients who did not require it. 294

295 The FEF 25-75% and mMRC parameters were robust diagnostic indicators of the patient recovery 296 process, given that these respiratory responses were the most variable and had the highest 297 discrimination capacity. This might be associated with changes in the small airway that are equivalent 298 to approximately 80% of the extension of the lung parenchyma (35). Given that FEF 25-75% is the 299 only spirometric measurement that assesses the small-caliber airway, additional studies that include 300 more specific diagnostic methods for assessing changes in lung function in the small-caliber airway 301 are needed (36-38). The long-term impacts of the sequelae of Covid-19 also merit further 302 investigation; the use of a large sample of patients is needed to improve the ability to detect changes 303 in respiratory function before and after therapy.

304	We found that PR had positive effects on recovery from respiratory pathologies caused by SARS-
305	CoV infection and that it accelerated the recovery process. However, which techniques are optimal
306	and how long the rehabilitation program should last remain unclear given that benefits have been
307	observed in 2-week programs (29,39). Other studies have reported benefits in 6-week programs (28);
308	in our study, positive effects were observed in a 12-week program (40).
309	PR accelerated the recovery of lung function and the perception of dyspnea in patients diagnosed with
310	Covid-19. However, additional studies are needed to clarify whether rehabilitation method and
311	program duration affect the benefits observed; the effectiveness of remote rehabilitation procedures
312	such as Telemedicine also merits further study. Given the difficulty of access to medical facilities in
313	Colombia, special effort is needed to ensure equal access to comprehensive care.
314	
315	Conclusions
316	• A 12-week PR program resulted in significant changes in lung function in Colombian
317	patients.
318	• The most pronounced changes were observed in the perception of dyspnea, FVC, and FEV1.
319	Age, height, weight, and the presence of comorbidities were not correlated with significant
320	changes observed between groups.
321	• Patients with a history of using positive pressure devices such as NIMV and IMV had FVC
321 322	• Patients with a history of using positive pressure devices such as NIMV and IMV had FVC values less than 70%, a pattern that is associated with restrictive diseases.
322	values less than 70%, a pattern that is associated with restrictive diseases.
322 323	 values less than 70%, a pattern that is associated with restrictive diseases. FEF 25-75 and MRC are robust diagnostic indicators of the patient recovery process given

328 **Conflicts of interest**

The researchers that participated in this research do not report any conflict of interest. The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

332 Funding

333 The authors report no involvement in the research by the sponsor that could have influenced the 334 outcome of this work.

335 Authors' contributions

Carlos Duvan Páez-Mora and author Carolina Zona-Rubio conceived and designed the study and wrote the manuscript; Teddy Angarita-Sierra analyzed and interpreted the data and wrote the manuscript; and Matilde E Rojas-Paredes and Daniela Cano-Trejos conceived the study and collected data. All authors contributed to drafts of the manuscript, and Carolina Zona-Rubio and Teddy Angarita-Sierra revised the manuscript. All authors read and approved the final version of the manuscript.

All authors contributed equally to the manuscript and read and approved the final version of themanuscript.

344 Acknowledgments

We thank the Neumocesar Pneumological Center and Doctor Edinson Valencia for their constant support and commitment to this research. We thank Christopher K Akcali for revising a draft of the manuscript.

349 **References**

- CEPAL SE. La pandemia de enfermedad por Coronavirus Covid-19. CEPAL-UNDRR
 [Internet]. Vol. 1, Center for Disease Control and Prevention. 2021 [cited 2022 Oct 3].
 Available from: https://www.paho.org/en/topics/coronavirus-infections/coronavirus disease-covid-19-pandemic
- Peramo-Álvarez FP, López-Zúñiga MÁ, López-Ruz MÁ. Medical sequels of COVID-19
 [Internet]. Vol. 157, Medicina Clinica. Elsevier; 2021 [cited 2022 Oct 3]. p. 388–94.
 Available from: /pmc/articles/PMC8157124/
- Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, Solis-Navarro L, Burgos F,
 Puppo H, et al. Respiratory function in patients post-infection by COVID-19: a systematic
 review and meta-analysis [Internet]. Vol. 27, Pulmonology. Elsevier; 2021 [cited 2022 Oct
 3]. p. 328–37. Available from: /pmc/articles/PMC7687368/
- 4. Naretto O, Emilio Á, Patricia PM, Angélica SM. Fisiopatología Pulmonar de la COVID-19.
 Rev Am Med Respir [Internet]. 2020 [cited 2022 Oct 3];4:402–9. Available from: http://www.ramr.org/articulos/volumen_20_numero_4/articulos_revision/articulos_revision
 fisiopatologia_pulmonar_de_la_covid-19.pdf
- Benítez-Pérez RE, Torre-Bouscoulet L, Villca-Alá N, Del-Río-Hidalgo RF, Pérez-Padilla R,
 Vázquez-García JC, et al. Espirometría: recomendaciones y procedimiento. NCT Neumol y
 Cirugía Tórax [Internet]. 2019 [cited 2022 Oct 22];78(S2):97–112. Available from:
 www.medigraphic.org.mx
- Kattainen S, Lindahl A, Vasankari T, Ollila H, Volmonen K, Piirilä P, et al. Lung function
 and exercise capacity 6 months after hospital discharge for critical COVID-19. BMC Pulm
 Med [Internet]. 2022 Dec 1 [cited 2022 Sep 14];22(1). Available from:
 https://pubmed.ncbi.nlm.nih.gov/35733179/
- 373 7. Ríos CPS. Función pulmonar y frecuencia de síndrome post-COVID-19 en pacientes

374		recuperados de neumonía por SARS-CoV-2 mediante enfoque completo de telemedicina.
375		Respirar [Internet]. 2021 [cited 2022 Oct 3];13:128–37. Available from:
376		https://alatorax.org/es/publicaciones/respirar/34/funcion-pulmonar-y-frecuencia-de-
377		sindrome-post-covid-19-en-pacientes-recuperados-de-neumonia-por-sars-cov-2-mediante-
378		enfoque-completo-de-telemedicina
379	8.	Chen H, Shi H, Liu X, Sun T, Wu J, Liu Z. Effect of Pulmonary Rehabilitation for Patients
380		With Post-COVID-19: A Systematic Review and Meta-Analysis. Front Med [Internet]. 2022
381		Feb 21 [cited 2022 Sep 14];9. Available from: https://pubmed.ncbi.nlm.nih.gov/35265644/
382	9.	Okan S, Okan F, Duran Yücesoy F. Evaluation of pulmonary function and exercise capacity
383		after COVID-19 pneumonia. Hear Lung [Internet]. 2022 Jul 1 [cited 2022 Sep 14];54:1-6.
384		Available from: https://pubmed.ncbi.nlm.nih.gov/35305515/
385	10	. Barker-Davies RM, O'Sullivan O, Senaratne KPP, Baker P, Cranley M, Dharm-Datta S, et
386		al. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. Br J Sports Med
387		[Internet]. 2020 Aug 1 [cited 2022 Sep 14];54(16):949–59. Available from:
388		https://pubmed.ncbi.nlm.nih.gov/32475821/
389	11	. Prunera-Pardell MJ, Padín-López S, Domenech-del Rio A, Godoy-Ramírez A. Efectividad
390		de un programa de rehabilitación respiratoria en pacientes con enfermedad pulmonar
391		obstructiva crónica. Enferm Clin. 2018 Jan 1;28(1):5-12.
392	12	. Liu K, Zhang W, Yang Y, Zhang J, Li Y, Chen Y. Respiratory rehabilitation in elderly
393		patients with COVID-19: A randomized controlled study. Complement Ther Clin Pract. 2020
394		May 1;39:101166.
395	13	. Paneroni M, Vogiatzis I, Bertacchini L, Simonelli C, Vitacca M. Predictors of Low Physical
396		Function in Patients With COVID-19 With Acute Respiratory Failure Admitted to a Subacute
397		Unit. Arch Phys Med Rehabil. 2021 Jun 1;102(6):1228-31.
571		
398	14	. Schaeffer MR, Cowan J, Milne KM, Puyat JH, Voduc N, Corrales-Medina V, et al.

400 COVID-19 fatigue. Respir Physiol Neurobiol [Internet]. 2022 Aug 1 [cited 2022 Sep 14];302. 401 Available from: https://pubmed.ncbi.nlm.nih.gov/35364291/ 402 15. Medical Research Council. MRC breathlessness scales: 1952 and 1959 – UKRI [Internet]. 403 1959 [cited 2023 Mar 2]. Available from: https://www.ukri.org/publications/mrc-404 breathlessness-scales-1952-and-1959/ 405 16. Fernando L, Serna C, Bernal GB, General S. USO E INTERPRETACION DE LA 406 ESPIROMETRIA [Internet]. 407 https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ENT/anexo-408 educativo-uso-espirometria.pdf. 2015 2023 [cited] Mar 7]. Available from: 409 https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ENT/anexo-410 educativo-uso-espirometria.pdf 411 17. Sokal R, Rohfl R. Biometría: los principios y la práctica de la estadística en la investigación 412 biológica. 1st ed. Francisco S, editor. W. H FREEMAN; 1981. 413 18. Ren S, Frymier PD. Use of multidimensional scaling in the selection of wastewater toxicity 414 test battery components. Water Res [Internet]. 2003 [cited 2022 Oct 22];37(7):1655-61. 415 Available from: https://pubmed.ncbi.nlm.nih.gov/12600394/ 416 19. Guisande C, Heine J, García-Roselló E, González-Dacosta J, Perez-Schofield BJG, 417 González-Vilas L, et al. FactorsR: An RWizard application for identifying the mostm likely 418 causal factors in controlling species Richness. Diversity. 2015;7(4):385-96. 419 20. Kruskal J, Wish M. Multidimensional Scaling [Internet]. 2455 Teller Road, Thousand Oaks 420 California 91320 United States of America: SAGE Publications, Inc.; 1978. 98 p. Available 421 from: https://methods.sagepub.com/book/multidimensional-scaling 422 21. Fox J, Weisberg S. An R companion to applied regression. SAGE, editor. 2019. 680 p. 423 22. Mac Nally R, Walsh CJ. Hierarchical partitioning public-domain software. Biodivers 424 Conserv [Internet]. 2004 Mar [cited 2022 Oct 22];13(3):659-60. Available from: 425 https://link.springer.com/article/10.1023/B:BIOC.0000009515.11717.0b

426	23.	Hui W, Gel YR, Gastwirth JL. Lawstat: An R package for law, public policy and biostatistics.
427		J Stat Softw [Internet]. 2008 [cited 2022 Oct 22];28(3). Available from:
428		https://www.academia.edu/33106134/lawstat_An_R_Package_for_Law_Public_Policy_and
429		_Biostatistics
430	24.	Gross J, Ligges U. nortest: Tests for normality. https//CRANR-project.org/package=nortest,
431		R Packag version 10-4. 2015;
432	25.	Ridout MS, Linkie M. Estimating overlap of daily activity patterns from camera trap data. J
433		Agric Biol Environ Stat [Internet]. 2009 [cited 2023 Mar 17];14(3):322-37. Available from:
434		https://link.springer.com/article/10.1198/jabes.2009.08038
435	26.	Maintainer B, Bolar K. Title Interactive Document for Working with Basic Statistical
436		Analysis. 2022 [cited 2023 Mar 17]; Available from:
437		https://jarvisatharva.shinyapps.io/StatisticsPrimer/
438	27.	Naimi B, Hamm NAS, Groen TA, Skidmore AK, Toxopeus AG. Where is positional
439		uncertainty a problem for species distribution modelling? Ecography (Cop). 2014
440		Feb;37(2):191–203.
441	28.	Liu S ting, Zhan C, Ma Y jing, Guo C yang, Chen W, Fang X ming, et al. Effect of qigong
442		exercise and acupressure rehabilitation program on pulmonary function and respiratory
443		symptoms in patients hospitalized with severe COVID-19: a randomized controlled trial.
444		Integr Med Res [Internet]. 2021 Jan 1 [cited 2022 Sep 14];10(Suppl). Available from:
445		https://pubmed.ncbi.nlm.nih.gov/34733607/
446	29.	Benavides-Cordoba V, Barros-Poblete M, Vieira RP, Mazzucco G, Fregonezi G, Torres-
447		Castro R. Provision of pulmonary rehabilitation in Latin America 18 months after the
448		COVID-19 pandemic: A survey of the Latin American Thoracic Association. Chron Respir
449		Dis [Internet]. 2022 May 1 [cited 2022 Sep 14];19. Available from:
450		https://pubmed.ncbi.nlm.nih.gov/35616253/
451	30.	Zhu P, Wang Z, Guo X, Feng Z, Chen C, Zheng A, et al. Pulmonary Rehabilitation

- Accelerates the Recovery of Pulmonary Function in Patients With COVID-19. Front
 Cardiovasc Med [Internet]. 2021 Jul 20 [cited 2022 Sep 14];8. Available from:
 https://pubmed.ncbi.nlm.nih.gov/34355029/
- 455 31. Puchner B, Sahanic S, Kirchmair R, Pizzini A, Sonnweber B, Wöll E, et al. Beneficial effects
 456 of multi-disciplinary rehabilitation in postacute COVID-19: an observational cohort study.
 457 Eur J Phys Rehabil Med [Internet]. 2021 Apr 1 [cited 2022 Sep 14];57(2):189–98. Available
 458 from: https://pubmed.ncbi.nlm.nih.gov/33448756/
- 32. Pleguezuelos E, Del Carmen A, Llorensi G, Carcole J, Casarramona P, Moreno E, et al.
 Severe loss of mechanical efficiency in COVID-19 patients. J Cachexia Sarcopenia Muscle
 [Internet]. 2021 Aug 1 [cited 2022 Sep 14];12(4):1056–63. Available from:
 https://pubmed.ncbi.nlm.nih.gov/34102017/
- 33. Swenson KE, Swenson ER. Pathophysiology of Acute Respiratory Distress Syndrome and
 COVID-19 Lung Injury. Crit Care Clin. 2021 Oct 1;37(4):749–76.
- 34. Roberts P, Wertheimer J, Park E, Nuño M, Riggs R. Identification of Functional Limitations
 and Discharge Destination in Patients With COVID-19. Arch Phys Med Rehabil. 2021 Mar
 1;102(3):351–8.
- 468 35. Lipworth B, Manoharan A, Anderson W. Unlocking the quiet zone: the small airway asthma
 469 phenotype. Lancet Respir Med. 2014 Jun 1;2(6):497–506.
- 470 36. McNulty W, Usmani OS. Techniques of assessing small airways dysfunction. Eur Clin Respir
 471 J [Internet]. 2014 Jan [cited 2023 Feb 21];1(1):25898. Available from:
 472 /pmc/articles/PMC4629724/
- 473 37. Fusco A, Padua L, Coraci D, Loreti C, Castelli L, Costantino C, et al. Developing pulmonary
 474 rehabilitation for COVID-19: Are we linked with the present literature? a lexical and
 475 geographical evaluation study based on the graph theory [Internet]. Vol. 10, Journal of
 476 Clinical Medicine. J Clin Med; 2021 [cited 2022 Sep 14]. Available from:
 477 https://pubmed.ncbi.nlm.nih.gov/34945063/

478	38.	Lorent N, Weygaerde Y Vande, Claeys E, Fajardo IGC, De Vos N, De Wever W, et al.
479		Prospective longitudinal evaluation of hospitalised COVID-19 survivors 3 and 12 months
480		after discharge. ERJ Open Res [Internet]. 2022 [cited 2022 Sep 14];8(2). Available from:
481		https://pubmed.ncbi.nlm.nih.gov/35415186/
482	39.	Rayegani SM, Bozorgmehr R, Oshnari LA, Kaghazi AHM. The Effect of Exercise-Based
483		Pulmonary Rehabilitation on Quality of Life in Recovered COVID-19 Patients; a Quasi-
484		Experimental Study. Arch Acad Emerg Med [Internet]. 2022 [cited 2022 Sep 14];10(1).
485		Available from: https://pubmed.ncbi.nlm.nih.gov/35765605/
486	40.	Hayden MC, Limbach M, Schuler M, Merkl S, Schwarzl G, Jakab K, et al. Effectiveness of
487		a three-week inpatient pulmonary rehabilitation program for patients after covid-19: A
488		prospective observational study. Int J Environ Res Public Health [Internet]. 2021 Sep 1 [cited
489		2022 Sep 14];18(17). Available from: https://pubmed.ncbi.nlm.nih.gov/34501596/